 The European Medicines Agencys Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion recommending conditional approval for Calliditas Therapeutics ABs NASDAQ: CALT Kinpeygo for primary immunoglobulin A IgA nephropathy IgAN. The. 